CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Cynomolgus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

Flow Cytometry: CD20 Antibody (10F381 (rituximab)) - Chimeric [NBP2-52646] - Flow-cytometry using the anti-CD20 research biosimilar antibody Rituximab. Rhesus monkey lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Rituximab (NBP2-52646, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.

• Reactivity: Hu, Pm-Cm, RM
• Applications: Flow, CyTOF-ready
• Clone: 10F381 (rituximab)
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free Summary

• Description: Novus Biologicals Rabbit CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free (NBP2-52646) is a recombinant monoclonal antibody validated for use in Flow. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Human lymphoblastoid cell line SB.
• Specificity: CD20 (Human B-lymphocyte-restricted differentiation antigen, Bp35), is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kDa located on pre-B and mature B lymphocytes, and most B-cell non-Hodgkin's lymphomas, but is not found on stem cells, pro-B cells, normal plasma cells or other normal tissues .
• Isotype: IgG Kappa
• Clonality: Monoclonal
• Host: Rabbit
• Gene: MS4A1
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 1:10 - 1:1000
• Application Notes: This antibody is Cytof ready. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for CD20 Antibody (10F381 (rituximab)) - Chimeric - Azide and BSA Free

• B1
• biosimilar antibody
• biosimilars
• B-lymphocyte antigen CD20
• B-lymphocyte cell-surface antigen B1
• B-lymphocyte surface antigen B1
• Bp35
• Bp35MGC3969
• CD20 antigen
• CD20 receptor
• CD20
• CD20S7
• CVID5
• LEU-16
• Leukocyte surface antigen Leu-16
• Ly-44
• Membrane-spanning 4-domains subfamily A member 1
• membrane-spanning 4-domains, subfamily A, member 1
• MS4A1
• MS4A2
• S7

Background

CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).

References

1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MS4A1